Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

medRxiv logoLink to medRxiv
[Preprint]. 2020 May 8:2020.05.04.20090944. [Version 1] doi: 10.1101/2020.05.04.20090944

Acute Kidney Injury in Hospitalized Patients with COVID-19

Lili Chan, Kumardeep Chaudhary, Aparna Saha, Kinsuk Chauhan, Akhil Vaid, Mukta Baweja, Kirk Campbell, Nicholas Chun, Miriam Chung, Priya Deshpande, Samira S Farouk, Lewis Kaufman, Tonia Kim, Holly Koncicki, Vijay Lapsia, Staci Leisman, Emily Lu, Kristin Meliambro, Madhav C Menon, Joshua L Rein, Shuchita Sharma, Joji Tokita, Jaime Uribarri, Joseph A Vassalotti, Jonathan Winston, Kusum S Mathews, Shan Zhao, Ishan Paranjpe, Sulaiman Somani, Felix Richter, Ron Do, Riccardo Miotto, Anuradha Lala, Arash Kia, Prem Timsina, Li Li, Matteo Danieletto, Eddye Golden, Patricia Glowe, Micol Zweig, Manbir Singh, Robert Freeman, Rong Chen, Eric Nestler, Jagat Narula, Allan C Just, Carol Horowitz, Judith Aberg, Ruth JF Loos, Judy Cho, Zahi Fayad, Carlos Cordon-Cardo, Eric Schadt, Matthew A Levin, David L Reich, Valentin Fuster, Barbara Murphy, John Cijiang He, Alexander W Charney, Erwin P Bottinger, Benjamin S Glicksberg, Steven G Coca, Girish N Nadkarni
PMCID: PMC7274245  PMID: 32511564

Abstract

Importance: Preliminary reports indicate that acute kidney injury (AKI) is common in coronavirus disease (COVID)-19 patients and is associated with worse outcomes. AKI in hospitalized COVID-19 patients in the United States is not well-described. Objective: To provide information about frequency, outcomes and recovery associated with AKI and dialysis in hospitalized COVID-19 patients. Design: Observational, retrospective study. Setting: Admitted to hospital between February 27 and April 15, 2020. Participants: Patients aged ≥18 years with laboratory confirmed COVID-19 Exposures: AKI (peak serum creatinine increase of 0.3 mg/dL or 50% above baseline). Main Outcomes and Measures: Frequency of AKI and dialysis requirement, AKI recovery, and adjusted odds ratios (aOR) with mortality. We also trained and tested a machine learning model for predicting dialysis requirement with independent validation. Results: A total of 3,235 hospitalized patients were diagnosed with COVID-19. AKI occurred in 1406 (46%) patients overall and 280 (20%) with AKI required renal replacement therapy. The incidence of AKI (admission plus new cases) in patients admitted to the intensive care unit was 68% (553 of 815). In the entire cohort, the proportion with stages 1, 2, and 3 AKI were 35%, 20%, 45%, respectively. In those needing intensive care, the respective proportions were 20%, 17%, 63%, and 34% received acute renal replacement therapy. Independent predictors of severe AKI were chronic kidney disease, systolic blood pressure, and potassium at baseline. In-hospital mortality in patients with AKI was 41% overall and 52% in intensive care. The aOR for mortality associated with AKI was 9.6 (95% CI 7.4-12.3) overall and 20.9 (95% CI 11.7-37.3) in patients receiving intensive care. 56% of patients with AKI who were discharged alive recovered kidney function back to baseline. The area under the curve (AUC) for the machine learned predictive model using baseline features for dialysis requirement was 0.79 in a validation test. Conclusions and Relevance: AKI is common in patients hospitalized with COVID-19, associated with worse mortality, and the majority of patients that survive do not recover kidney function. A machine-learned model using admission features had good performance for dialysis prediction and could be used for resource allocation.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from medRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES